Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

AKBA / Akebia Therapeutics, Inc. / Nantahala Capital Management, LLC - SCHEDULE 13G/A (Passive Investment)

2018-02-14 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   AKEBIA THERAPEUTICS, INC. (Name of Issuer)   Common Stock, $0.00001 par value (Title of Class of Securities)   00972D105 (CUSIP Number)   December 31, 2017 (Date of Event which Requires Filing of this Statement)    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ R

AKBA / Akebia Therapeutics, Inc. / Nantahala Capital Management, LLC - SCHEDULE 13G/A (Passive Investment)

2018-02-14 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   AKEBIA THERAPEUTICS, INC. (Name of Issuer)   Common Stock, $0.00001 par value (Title of Class of Securities)   00972D105 (CUSIP Number)   December 31, 2017 (Date of Event which Requires Filing of this Statement)    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ R

Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment

2018-02-14 seekingalpha
Today we will focus on Akebia Therapeutics (AKBA) after the company provided an update to investors on its late-stage vadadustat studies. (252-3)

AKBA / Akebia Therapeutics, Inc. / Novo A/S - SC 13G (Passive Investment)

2018-02-13 sec.gov
SC 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     Akebia Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) 00972D 10 5 (CUSIP number) February 2, 2018 (Date of event which requires filing of this statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d)   *

AKBA / Akebia Therapeutics, Inc. / Novo A/S - SC 13G (Passive Investment)

2018-02-13 sec.gov
SC 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     Akebia Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) 00972D 10 5 (CUSIP number) February 2, 2018 (Date of event which requires filing of this statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d)   *

AKBA / Akebia Therapeutics, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us00972d1054_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) AKEBIA THERAPEUTICS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 00972D105 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------------

AKBA / Akebia Therapeutics, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us00972d1054_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) AKEBIA THERAPEUTICS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 00972D105 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------------

AKBA / Akebia Therapeutics, Inc. S-8

2018-01-26 sec.gov
S-8 As filed with the Securities and Exchange Commission on January 26, 2018 Registration No. 333-                   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   20-8756903 (State or other jurisdiction of incorporation or organization)   (I.

AKBA / Akebia Therapeutics, Inc. / EAGLE ASSET MANAGEMENT INC - 3G/A (Passive Investment)

2018-01-08 sec.gov
1/8/18 Securities and Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: Schedule 13G Akebia Theraputics inc As of 12/31/2017 Gentlemen: In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing a beneficial ownership change of 1% or more as of 12/31/17 filed on behalf of Eagle Asset Management, Inc.

AKBA / Akebia Therapeutics, Inc. / EAGLE ASSET MANAGEMENT INC - 3G/A (Passive Investment)

2018-01-08 sec.gov
1/8/18 Securities and Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: Schedule 13G Akebia Theraputics inc As of 12/31/2017 Gentlemen: In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing a beneficial ownership change of 1% or more as of 12/31/17 filed on behalf of Eagle Asset Management, Inc.

Local Teens in Boston Raise $10,000 for Families in Need

2017-12-20 accesswire
BOSTON, MA / ACCESSWIRE / December 20, 2017 / In September, three friends hatched a plan to "be Santa for a day" in order to help children with disabilities whose families were in need. Thanks to their efforts, which raised $10,000 with the generous help of area businesses and nonprofits, 15 families will have a brighter holiday. (17-0)

Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

2017-12-13 zacks
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. (57-0)

Top Analyst Upgrades and Downgrades: Amazon, Allergan, Borg Warner, Lam Research, Mellanox Technologies, Shake Shack and More

2017-12-07 247wallst
The futures are down this morning as the markets continue to swirl in anticipation of a tax reform package. While the House and the Senate are continuing to work on the details, the market is in standby mode until completion. The one trend that has dominated this bull market is that investors keep finding new reasons to buy stocks after every single sell-off. Those same investors are looking for new investment and trading ideas to generate gains and income. (210-1)

Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)

2017-12-07 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. (55-0)

Zacks.com featured expert Kevin Matras highlights: Chef's Warehouse, Easterly Government Properties, Opus Bank, TowneBank and UGI

2017-12-06 zacks
Chicago, IL – December 6, 2017 - Stocks in this week’s article include: The Chef’s Warehouse (CHEF - Free Report) , Easterly Government Properties (DEA - Free Report) , Opus Bank (OPB - Free Report) , TowneBank (TOWN - Free Report) and UGI Corp. (UGI - Free Report) . Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. (880-0)


CUSIP: 00972D105